Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers. 2014

Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba-shi 260-8675, Chiba, Japan.

BACKGROUND We have previously identified the cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3) mRNA in several human colon and lung cancer tissues. Ct-OATP1B3 is a variant of the liver-type OATP1B3 (Lt-OATP1B3) mRNA, which is a hepatocyte plasma membrane transporter with broad substrate specificity. However, in cancer tissues, both the detailed characteristics of Ct-OATP1B3 mRNA expression and its biological functions remain unclear. With this point in mind, we sought to characterize Ct-OATP1B3 mRNA expression in colon and lung cancer tissues. In addition, we attempted to obtain functional implication of Ct-OATP1B3 in cancer cells. METHODS Matched pairs of cancer and normal tissues were collected from 39 colon cancer and 28 lung cancer patients. The OATP1B3 mRNA expression levels in each of these tissues were separately determined by quantitative real-time polymerase chain reaction. Mann-Whitney U test and Fisher's exact test were used in statistical analysis. The Ct-OATP1B3 functional expression in colon cancer cells was then examined by Western blotting and transport analyses. RESULTS Ct-OATP1B3 mRNA, but not Lt-OATP1B3 mRNA, was abundantly expressed in colon cancer tissues at a higher detection frequency (87.2%) than that of the adjacent normal tissues (2.6%). Furthermore, it was found that Ct-OATP1B3 mRNA expression was often detected in early colon cancer stages (88.9%, n = 18), and that its expression was associated with well-differentiated colon cancer statuses. On the other hand, Ct-OATP1B3 mRNA also showed a predominant and cancer-associated expression profile in lung tissues, although at frequencies and expression levels that were lower than those obtained from colon cancer. As for attempts to clarify the Ct-OATP1B3 functions, neither protein expression nor transport activity could be observed in any of the cell lines examined. CONCLUSIONS Based on the unique characteristics of the Ct-OATP1B3 mRNA expression profile identified in this study, Ct-OATP1B3 mRNA can be expected to become a biomarker candidate for use in colon (and lung) cancer diagnosis. Simultaneously, our results advance the possibility that Ct-OATP1B3 might play yet unidentified roles, in addition to transporter function, in cancer cell biology.

UI MeSH Term Description Entries

Related Publications

Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
November 2013, Pharmaceutical research,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
November 2011, Yao xue xue bao = Acta pharmaceutica Sinica,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
January 2018, Drug metabolism letters,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
March 2010, Pharmaceutical research,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
January 2017, PloS one,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
June 2020, Korean journal of radiology,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
May 2024, Toxicology in vitro : an international journal published in association with BIBRA,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
February 2012, Biochemical and biophysical research communications,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
June 2020, World journal of surgical oncology,
Yuchen Sun, and Tomomi Furihata, and Seiya Ishii, and Miki Nagai, and Manami Harada, and Osamu Shimozato, and Takehiko Kamijo, and Shinichiro Motohashi, and Ichiro Yoshino, and Atsuko Kamiichi, and Kaoru Kobayashi, and Kan Chiba
September 2022, Molecular pharmacology,
Copied contents to your clipboard!